New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio

01 December 2022 | Thursday | News

ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license agreement granting Japan's Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio.
Image Source : Public Domain

Image Source : Public Domain

ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 100 patents are held worldwide.

Eric Rhodes, CEO at ERS had the following statement"CRISPR/Cas9 is a powerful genome engineering tool that has revolutionized biotechnology. At ERS we are committed to making our technology accessible and available. We are pleased to support Cosmo Bio, a leader in high performance research biotools, in their ongoing development with this license agreement."

Cosmo Bio's mission is to provide the latest information on technological advancements and products from trusted manufacturers for establishments involved in biology, such as educational organizations, research institutions, and inspection agencies worldwide.

Cosmo Bio is the latest licensee for ERS Genomics in Japan.  Speaking in reference to ERS'  presence in Japan, Eric further commented:

"Japan is one of the world's leading pharma and medtech markets and sets global benchmarks in terms of innovation and delivery. The licenses we issue in Japan are clear indicators to us that accelerated growth and accompanying opportunities in the life science sector will continue in this region for the foreseeable future."   


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in